07:53 AM EDT, 09/16/2025 (MT Newswires) -- Novo Nordisk ( NVO ) intends to file a request with the US Food and Drug Administration for approval of a higher dose version of its weigh-loss drug Wegovy, Bloomberg reported Tuesday.

Chief Scientific Officer Martin Holst Lange said that at a higher dose Wegovy is just as effective as Eli Lilly's (LLY) Zepbound, according to the report.

"Obviously our competitors have optimized the dosing," Lange told Bloomberg in an interview. "Now with high-dose Wegovy we've done the same."

Novo Nordisk ( NVO ) did not immediately respond to a request for comment from MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)